Proqr Therapeutics
(PRQR)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -9,505 | -68,369 | -53,886 | -30,990 | -16,216 |
| Depreciation Amortization | 589 | 2,656 | 1,786 | 1,236 | 640 |
| Other Working Capital | 56,128 | -5,725 | 233 | -3,442 | -4,549 |
| Other Operating Activity | 795 | -742 | 828 | -4,382 | -2,843 |
| Operating Cash Flow | $48,008 | $-72,180 | $-51,040 | $-37,578 | $-22,968 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -96 | -740 | -726 | -506 | -274 |
| Investing Cash Flow | $-96 | $-740 | $-726 | $-506 | $-274 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | -45,697 | -43,685 | N/A | N/A |
| Common Stock Issued | N/A | 14,915 | 33 | 35 | 37 |
| Other Financing Activity | -278 | -1,764 | -1,323 | -993 | -646 |
| Financing Cash Flow | $-278 | $-32,546 | $-44,976 | $-958 | $-609 |
| Exchange Rate Effect | -178 | 7,745 | 9,022 | 5,921 | 1,506 |
| Beginning Cash Position | 101,732 | 197,575 | 188,874 | 199,563 | 210,439 |
| End Cash Position | 149,188 | 99,855 | 101,154 | 166,443 | 188,094 |
| Net Cash Flow | $47,456 | $-97,720 | $-87,720 | $-33,120 | $-22,345 |
| Free Cash Flow | |||||
| Operating Cash Flow | 48,008 | -72,180 | -51,040 | -37,578 | -22,968 |
| Capital Expenditure | -146 | -746 | -726 | -506 | -274 |
| Free Cash Flow | 47,862 | -72,926 | -51,766 | -38,084 | -23,242 |